by Syner-G | Nov 8, 2023 | Press Releases
November 8, 2023, Boston, MA Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, announced today that it has been named a BioSpace 2024 Best Place to...
by Syner-G | Nov 1, 2023 | Blog
Biopharmaceutical development is an extensive and complex process. Managing processes like Investigational New Drug (IND) applications or the manufacturing, quality, and regulatory side of the processes—collectively known as CMC, or the Chemistry, Manufacturing and...
by Syner-G | Nov 1, 2023 | Case Studies
Challenge The client lacked the internal resources to review and validate its strategy and approach to its first commercial program. They needed CMC support for their first drug which has “breakthrough” designation. The client embraced the outsourced model and knew it...
by Syner-G | Oct 27, 2023 | Blog
Bringing a new drug to market is a complex process that can take years with no guarantee of a successful outcome. The journey is highly regulated and includes numerous processes that require drug developers to have multiple levels of expertise within their teams. One...
by Syner-G | Oct 26, 2023 | Press Releases
Murray to Spearhead Newly Integrated Department October 26, 2023, Boston, MA —Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, announced the...
